Early human trials of the CBL-514 injection showed a 12% average reduction in dangerous visceral fat, alongside weight loss and improvements in blood pressure and cholesterol.
Early human trials of the CBL-514 injection showed a 12% average reduction in dangerous visceral fat, alongside weight loss and improvements in blood pressure and cholesterol.